Clinical Context
A typical patient is a postmenopausal woman with estrogen receptor–positive, HER2-negative metastatic or locally advanced breast cancer who has progressed on prior endocrine therapy. The oncology clinic schedules an outpatient infusion visit for administration of intramuscular fulvestrant, J9393 (fulvestrant, 25 mg single-dose vial, specific brand Teva not therapeutically equivalent to J9395).
At the visit the clinician documents diagnosis(es), reviews prior therapies, confirms indication for fulvestrant, obtains informed consent, and assesses for contraindications and potential drug interactions. Nursing verifies identity, reviews allergies, obtains baseline vital signs, and prepares the medication per product labeling. Fulvestrant is administered as a deep intramuscular injection (typically into the gluteal muscle) using appropriate aseptic technique. Observation for immediate adverse reactions follows, and the patient receives scheduling for follow-up doses (per dosing schedule) and documentation of lot number, expiration date, dose, route, site, and any administered ancillary medications (e.g., antiemetics or premedication if clinically indicated).
Typical site of service is an outpatient infusion/injection center or oncology clinic procedure room. The clinical workflow includes medication preparation by pharmacy, verification of billing code J9393, application of the appropriate modifier(s) when indicated, and documentation to support medical necessity for oncology drug benefit coverage and payer adjudication.